JAMES ELLIOTT BRADNER, MD
Osteopathic Medicine at Binney St, Boston, MA
License number
Massachusetts 216495
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
44 Binney St, Boston, MA 02115
129 Franklin St #317, Cambridge, MA 02139
129 Franklin St #317, Cambridge, MA 02139
Phone
(617) 632-6629
(617) 632-5168 (Fax)
(617) 549-4786
(617) 632-5168 (Fax)
(617) 549-4786
Personal information
See more information about JAMES ELLIOTT BRADNER at radaris.comName
Address
Phone
6 Buckskin Dr, Weston, MA 02493
129 Franklin St APT 412, Cambridge, MA 02139
23 Sidney St, Cambridge, MA 02139
9 Rollins Ct, Cambridge, MA 02139
134 Appleton St, Cambridge, MA 02138
Professional information
James Elliott Bradner, Boston MA
Specialties:
Internist
Address:
44 Binney St, Boston, MA 02115
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Small Molecule Printing
US Patent:
2013026, Oct 3, 2013
Filed:
Oct 10, 2012
Appl. No.:
13/648667
Inventors:
David W. Barnes - Cambridge MA, US
Angela N. Koehler - Cambridge MA, US
James Elliot Bradner - Cambridge MA, US
Ralph Mazitschek - Belmont MA, US
Stuart L. Schreiber - Boston MA, US
Angela N. Koehler - Cambridge MA, US
James Elliot Bradner - Cambridge MA, US
Ralph Mazitschek - Belmont MA, US
Stuart L. Schreiber - Boston MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
President and Fellows of Harvard College - Cambridge MA
President and Fellows of Harvard College - Cambridge MA
International Classification:
G01N 33/68
US Classification:
506 15
Abstract:
The present invention provides compositions and methods to facilitate the identification of compounds that are capable of interacting with a biological macromolecule of interest. In one aspect, a composition is provided that comprises an array of one or more types of chemical compounds attached to a solid support using isocyanate or isothiocyanate chemistry, wherein the density of the array of compounds is at least 1000 spots per cm. In general, these inventive arrays are generated by: (1) providing a solid support, wherein said solid support is functionalized with an isocyanate or isothiocyanate moiety capable of interacting with a desired chemical compound to form a covalent attachment; (2) providing one or more solutions of one or more types of compounds to be attached to the solid support; (3) delivering said one or more types of compounds to the solid support; and (4) catalyzing the attachment of the compound to the solid support, whereby an array is formed and the array of compounds has a density of at least 1000 spots per cm. In another aspect, the present invention provides methods for utilizing these arrays to identify small molecule partners for biological macromolecules of interest.
Small Molecule Printing
US Patent:
2009022, Sep 3, 2009
Filed:
Jan 3, 2007
Appl. No.:
12/159481
Inventors:
David W. Barnes - Newton MA, US
Angela N. Koehler - Cambridge MA, US
James E. Bradner - Cambridge MA, US
Ralph Mazitschek - Arlington MA, US
Stuart L. Schreiber - Boston MA, US
Angela N. Koehler - Cambridge MA, US
James E. Bradner - Cambridge MA, US
Ralph Mazitschek - Arlington MA, US
Stuart L. Schreiber - Boston MA, US
International Classification:
C40B 30/04, C40B 40/04, C40B 50/12
US Classification:
506 9, 506 15, 506 29
Abstract:
The present invention provides compositions and methods to facilitate the identification of compounds that are capable of interacting with a biological macromolecule of interest. In one aspect, a composition is provided that comprises an array of one or more types of chemical compounds attached to a solid support using isocyanate or isothiocyanate chemistry, wherein the density of the array of compounds is at least 1000 spots per cm. In general, these inventive arrays are generated by: (1) providing a solid support, wherein said solid support is functionalized with an isocyanate or isothiocyanate moiety capable of interacting with a desired chemical compound to form a covalent attachment; (2) providing one or more solutions of one or more types of compounds to be attached to the solid support; (3) delivering said one or more types of compounds to the solid support; and (4) catalyzing the attachment of the compound to the solid support, whereby an array is formed and the array of compounds has a density of at least 1000 spots per cm. In another aspect, the present invention provides methods for utilizing these arrays to identify small molecule partners for biological macromolecules of interest.
Compositions And Methods For Modulating Metabolism
US Patent:
2013025, Sep 26, 2013
Filed:
May 16, 2011
Appl. No.:
13/697963
Inventors:
James Elliott Bradner - Boston MA, US
Jonathan Brown - Brookline MA, US
Jorge Plutzky - Chestnut Hill MA, US
Jonathan Brown - Brookline MA, US
Jorge Plutzky - Chestnut Hill MA, US
International Classification:
C07D 495/14, A61K 31/7088
US Classification:
435375, 514220, 540560
Abstract:
The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.
Bifunctional Histone Deacetylase Inhibitors
US Patent:
8222423, Jul 17, 2012
Filed:
Feb 14, 2007
Appl. No.:
12/279440
Inventors:
James Elliot Bradner - Cambridge MA, US
Ralph Mazitschek - Arlington MA, US
Tang Weiping - Cambridge MA, US
Stuart S. Schreiber - Boston MA, US
Ralph Mazitschek - Arlington MA, US
Tang Weiping - Cambridge MA, US
Stuart S. Schreiber - Boston MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
President and Fellows of Harvard College - Cambridge MA
Howard Hughes Medical Institute - Chevy Chase MD
President and Fellows of Harvard College - Cambridge MA
Howard Hughes Medical Institute - Chevy Chase MD
International Classification:
C07D 249/00, C07C 303/00
US Classification:
548255, 564 80, 564 84
Abstract:
In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e. g. , proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc. ) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.
Treatment Of Protein Degradation Disorders
US Patent:
2006023, Oct 26, 2006
Filed:
Mar 22, 2006
Appl. No.:
11/386959
Inventors:
Kenneth Anderson - Wellesley MA, US
James Bradner - Cambridge MA, US
Edward Greenberg - Newton MA, US
Teru Hideshima - Brookline MA, US
Nicholas Kwiatkowski - Auburn MA, US
Ralph Mazitschek - Boston MA, US
Stuart Schreiber - Boston MA, US
Jared Shaw - Cambridge MA, US
Stephen Haggarty - Boston MA, US
James Bradner - Cambridge MA, US
Edward Greenberg - Newton MA, US
Teru Hideshima - Brookline MA, US
Nicholas Kwiatkowski - Auburn MA, US
Ralph Mazitschek - Boston MA, US
Stuart Schreiber - Boston MA, US
Jared Shaw - Cambridge MA, US
Stephen Haggarty - Boston MA, US
International Classification:
A61K 51/00, A61K 39/395, A61K 33/36
US Classification:
424001490, 424155100, 424623000
Abstract:
The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Treatment Of Cancers Characterized By Chromosomal Rearrangement Of The Gene
US Patent:
8623853, Jan 7, 2014
Filed:
Jul 21, 2009
Appl. No.:
13/055381
Inventors:
Christopher French - Boston MA, US
Jon Aster - Lexington MA, US
Matthias Hofer - Chicago IL, US
James Bradner - Cambridge MA, US
Jon Aster - Lexington MA, US
Matthias Hofer - Chicago IL, US
James Bradner - Cambridge MA, US
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A01N 43/00, A01N 43/40, A01N 43/38, A01N 43/08, A01N 37/28, A61K 31/33, A61K 38/00, A61K 38/12, A61K 31/44, A61K 31/405, A61K 31/34, A61K 31/205
US Classification:
514183, 514 193, 514 199, 514352, 514415, 514469, 514507
Abstract:
The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds.
Method For Preparing Largazole Analogs And Uses Thereof
US Patent:
8217076, Jul 10, 2012
Filed:
Jul 16, 2009
Appl. No.:
12/504508
Inventors:
Robert M. Williams - Fort Collins CO, US
James E. Bradner - Cambridge MA, US
Albert Bowers - Boston MA, US
Tenaya Newkirk - Fort Collins CO, US
James E. Bradner - Cambridge MA, US
Albert Bowers - Boston MA, US
Tenaya Newkirk - Fort Collins CO, US
Assignee:
Colorado State University Research Foundation - Fort collins CO
Dana-Farber Cancer Institute - Boston MA
Dana-Farber Cancer Institute - Boston MA
International Classification:
A61K 31/24, A61K 31/195, A61K 31/165, C12N 9/99, C07C 229/02, C07C 251/00, C07C 233/88
US Classification:
514539, 514563, 514615, 564158, 560 37, 562440
Abstract:
Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof
US Patent:
8609678, Dec 17, 2013
Filed:
Apr 2, 2012
Appl. No.:
13/437672
Inventors:
John H. Van Duzer - Georgetown MA, US
Ralph Mazitschek - Belmont MA, US
Walter Ogier - Winchester MA, US
James E. Bradner - Cambridge MA, US
Guoxiang Huang - Kernersville NC, US
Dejian Xie - Shanghai, CN
Nan Yu - Shanghai, CN
Ralph Mazitschek - Belmont MA, US
Walter Ogier - Winchester MA, US
James E. Bradner - Cambridge MA, US
Guoxiang Huang - Kernersville NC, US
Dejian Xie - Shanghai, CN
Nan Yu - Shanghai, CN
Assignee:
Acetylon Pharmaceuticals - Boston MA
International Classification:
A01N 43/54, A61K 31/505, C07D 239/42, C07D 401/04, C07D 239/02
US Classification:
514275, 514256, 544332
Abstract:
The present invention relates to “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
Fluorinated Hdac Inhibitors And Uses Thereof
US Patent:
2013004, Feb 14, 2013
Filed:
Jan 5, 2011
Appl. No.:
13/520650
Inventors:
James Elliot Bradner - Cambridge MA, US
Ralph Mazitschek - Belmont MA, US
Ralph Mazitschek - Belmont MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
President and Fellows of Harvard College - Cambridge MA
President and Fellows of Harvard College - Cambridge MA
International Classification:
A61K 31/165, A61K 31/4045, C07C 239/14, A61P 35/00, A61K 31/40, C07D 213/56, A61K 31/44, C07D 209/14, C07D 207/333
US Classification:
514355, 548507, 514415, 564182, 514617, 548540, 514423, 546316
Abstract:
Fluorinated deacetylase inhibitors of the general formulae (I), (II), and (III): and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase activity as described herein (e.g., cancer, neurodegenerative diseases, inflammatory diseases).